CHB

China Biotech Innovation ETF

Fund Summary

The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.

Fund Objective

The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.

Why CHB?

High Growth Potential

CHB enables investors to access high growth potential through companies central to the development of biotechnology in China.

Targeted Exposure

CHB delivers targeted exposure to an emerging theme and industry.

ETF Efficiency

In a single trade, CHB delivers access to dozens of companies with high exposure to the biotech theme in China.

Fund Details As of 06/18/21

Key Facts

Ticker	CHB
Inception Date	09/22/20
CUSIP	37954Y251
ISIN	US37954Y2515
Bloomberg Index Ticker	SOLCHB
Primary Exchange	Nasdaq
Number of Holdings	34

Stats & Fees

Net Assets	$6,313,651
Net Asset Value (NAV)	$18.04
Shares Outstanding	350,000
Total Expense Ratio	0.67%

Distributions

30-Day SEC Yield	N/A
Distribution Frequency	Semi-Annually

Fund Documents

Fund Research

Fund Prices As of 06/18/21

NAV	$18.04	Daily Change	$0.21	1.17%
Market Price	$18.03	Daily Change	$0.09	0.49%
30-Day Median Bid-Ask Spread	0.64%

As of recent (03/31/21)	Fund NAV	Market Price	Index
Year-to-Date	-1.22%	-0.79%	-1.13%
1 Month	-4.56%	-5.03%	-4.56%
3 Months	-1.22%	-0.79%	-1.13%
Since Inception	6.89%	7.55%	7.21%
Year-to-Date	16.04%	16.50%	16.37%
1 Month	1.23%	1.60%	1.28%
3 Months	12.13%	11.53%	12.33%
Since Inception	25.58%	26.31%	26.18%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated.

Fund Characteristics As of 06/18/21

Return on Equity	6.40%
Weighted Avg. Market Cap	6,773 M
	2020	2021
Price-to-earnings	2,496.41	100.56
Price-to-book value	6.59	6.36

Source: AltaVista Research, LLC

Net Assets (%)	Ticker	Name	SEDOL	Market Price ($)	Shares Held	Market Value ($)
10.23	2269 HK	WUXI BIOLOGICS CAYMAN INC	BL6B9P1	17.02	37,950	645,772.31
8.20	300142 C2	WALVAX BIOTECHNOLOGY CO-A	BD5CG36	9.13	56,700	517,549.65
7.80	BGNE	BEIGENE LTD-ADR	BYYWPW6	321.81	1,531	492,691.11
7.05	300601 C2	SHENZHEN KANGT-A	BFY8HT2	21.65	20,571	445,358.61
6.77	000661 C2	CHANGCHUN HIGH-A	BD5CDB3	61.30	6,974	427,516.22
4.42	300676 C2	BGI GENOMICS CO LTD-A	BFY8H58	18.42	15,138	278,839.70
4.41	1177 HK	SINO BIOPHARMACEUTICAL	B00XSF9	1.00	279,900	278,706.57
4.41	300357 C2	ZHEJIANG WOLWO-A	BFY8GY0	10.28	27,100	278,668.52
4.27	ZLAB	ZAI LAB LTD-ADR	BD9GVY0	157.30	1,713	269,454.90
3.88	002007 C2	HUALAN BIOLOGI-A	BD5CL19	5.60	43,800	245,102.31
3.86	1548 HK	GENSCRIPT BIOTECH CORP	BD9Q2J2	4.23	57,550	243,526.10
3.59	603345 C1	FU JIAN ANJOY-A	BMXWM11	36.02	6,300	226,919.99
3.25	300009 C2	ANHUI ANKE BIO-A	BD5C829	2.36	87,080	205,354.14
3.06	300725 C2	PHARMABLOCK SC-A	BFY8HC5	23.65	8,181	193,458.34
2.62	600161 C1	BEIJING TIAN-A	BP3R9J4	5.00	33,057	165,227.42
2.40	002030 C2	DAAN GENE CO LTD-A	BD5CKW3	3.31	45,780	151,341.77
2.32	603392 C1	BEIJING WANTAI-A	BMXTWX4	39.17	3,740	146,484.42
2.32	002252 C2	SHANGHAI RAAS -A	BD5CPJ5	1.12	130,600	146,408.70
2.11	002422 C2	SICHUAN KELUN-A	BD5CL08	3.03	44,000	133,125.85
2.02	603127 C1	JOINN LABORATO-A	BK94819	27.76	4,600	127,673.91
1.74	1530 HK	3SBIO INC	BY9D3L9	1.42	77,600	109,956.07
1.18	300639 C2	GUANGDONG HYBR-A	BMQBTJ2	4.77	15,642	74,598.17
1.00	9966 HK	ALPHAMAB ONCOLOGY	BL6WGG4	2.74	23,000	62,958.10
0.99	1873 HK	VIVA BIOTECH HOLDINGS	BJBL0L5	1.33	46,900	62,226.43
0.83	9939 HK	KINTOR PHARMACEUTICAL LTD	BMDWVN6	6.63	7,900	52,408.19
0.76	002038 C2	BEIJING SL -A	BD5CJD7	1.62	29,600	48,078.66
0.72	000710 C2	BERRY GENOMICS CO LTD-A	BFFJRH2	4.59	9,855	45,244.57
0.66	6855 HK	ASCENTAGE PHARMA	BK9PZW2	5.51	7,500	41,349.46
0.64	2126 HK	JW CAYMAN THERAP	BN4NLR9	3.65	11,000	40,099.96
0.61	000078 C2	SHENZ NEPTUNUS-A	BD5CBK8	0.50	75,700	38,211.90
0.50	603387 C1	GETEIN BIOTECH INC-A	BFB4S90	4.78	6,600	31,578.21
0.45	688366 C1	SHANGHAI HAOHA-A	BLCD7D5	25.44	1,106	28,137.00
0.37	603363 C1	FUJIAN AONONG-A	BF2DZF1	1.48	15,820	23,393.49
0.34	002880 C2	SHENZHEN WEIGU-A	BMTCVX0	5.50	3,880	21,357.80
0.24		CASH		0.27	54,218	14,871.84

Holdings are subject to change.

Latest Premium / Discount As of 06/18/21

NAV	$18.04
Market Price	$18.03
Premium / (Discount)	($0.01)

Current View 2021 Q2 As of 06/18/21

Days at Premium	43
Days at NAV	0
Days at Discount	12
Greatest Premium	1.04%
Greatest Discount	-0.71%

Daily Premium / Discount History As of 06/18/21

Hover over the chart points for details

View Chart Explanation

Download Chart Data (.CSV)

How can the Fund trade at a premium/discount to its NAV?

The primary explanation is that timing discrepancies can arise between the NAV and the trading price of the Fund. Since shares of the Fund trade on the open market, prices are affected by the constant flow of information received by investors, corporations and financial institutions. Depending on how this changing information affects investor sentiment, shares of the Fund may deviate slightly from the value of the Fund's underlying assets. The NAV of the Fund is only calculated once a day (normally at 4:00 p.m. eastern time). As a result, shareholders may pay more than NAV when they buy Fund shares and receive less than NAV when they sell those shares, because shares are purchased and sold at current market prices. However, due to the creation and redemption process that is unique to ETFs, market makers are able to minimize these deviations from NAV by taking advantage of arbitrage opportunities.

What causes these time discrepancies?

Close of Trading Times. Although both the NAV and the daily market price of the Fund are generally calculated based on prices at the closing time of the exchange (generally 4:00 p.m. eastern time), slight differences in this timing may cause discrepancies.

Time of Last Trade. Trading of Global X funds generally takes place during normal trading hours (9:30 a.m. to 4:00 p.m. eastern time). However, it is important to note that the last trade - from which the closing price is determined - may not occur at exactly 4:00 p.m. eastern time. Therefore, changing market sentiment during the time difference may cause the NAV to deviate from the closing price.

International Holdings. The premiums and discounts for funds with significant holdings in international markets may be less accurate due to the different closing times of various international markets. Because the Funds trade during U.S. market hours while the underlying securities may not, the time lapse between the markets can result in differences between the NAV and the trading price.

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares typically do not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.

CHB